The medical technology firm reported $110.0 million in cash reserves as of June 30, 2026, with $19.6 million used in operations and fixed assets.
Orchestra BioMed reported a second-quarter GAAP loss of $0.38 per share, reflecting ongoing investment in operations and development. The company held $110.0 million in cash and marketable securities at the end of the period, providing a strong liquidity position.
Net cash used in operating activities and fixed asset purchases totaled $19.6 million during the quarter. The results follow prior periods of elevated spending as the company advances its pipeline of medical devices and therapies.
No immediate market reaction was disclosed in the release.